Author:
Brandhagen BreeAnn N,Tieszen Chelsea R,Ulmer Tara M,Tracy Maria S,Goyeneche Alicia A,Telleria Carlos M
Abstract
Abstract
Background
Changes in cell shape and plasticity in cytoskeletal dynamics are critically involved in cell adhesion, migration, invasion and the overall process of metastasis. Previous work in our laboratory demonstrated that the synthetic steroid mifepristone inhibited the growth of highly metastatic cancer cells, while simultaneously causing striking changes in cellular morphology. Here we assessed whether such morphological alterations developed in response to cytostatic concentrations of mifepristone are reversible or permanent, involve rearrangement of cytoskeletal proteins, and/or affect the adhesive capacity of the cells.
Methods
Cancer cell lines of the ovary (SKOV-3), breast (MDA-MB-231), prostate (LNCaP), and nervous system (U87MG) were exposed to cytostatic concentrations of mifepristone and studied by phase-contrast microscopy. The transient or permanent nature of the cytostasis and morphological changes caused by mifepristone was assessed, as well as the rearrangement of cytoskeletal proteins. De-adhesion and adhesion assays were utilized to determine if mifepristone-arrested and morphologically dysregulated cells had abnormal de-adhesion/adhesion dynamics when compared to vehicle-treated controls.
Results
Mifepristone-treated cells displayed a long, thin, spindle-like shape with boundaries resembling those of loosely adhered cells. Growth arrest and morphology changes caused by mifepristone were reversible in SKOV-3, MDA-MB-231 and U87MG, but not in LNCaP cells that instead became senescent. All cancer cell types exposed to mifepristone displayed greatly increased actin ruffling in association with accelerated de-adhesion from the culture plate, and delayed adhesion capacity to various extracellular matrix components.
Conclusions
Cytostatic concentrations of mifepristone induced alterations in the cellular structure of a panel of aggressive, highly metastatic cancer cells of different tissues of origin. Such changes were associated with re-distribution of actin fibers that mainly form non-adhesive membrane ruffles, leading to dysregulated cellular adhesion capacity.
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Genetics,Oncology
Reference62 articles.
1. Fedele L, Berlanda N: Emerging drugs for endometriosis. Expert Opin Emerg Drugs. 2004, 9 (1): 167-177.
2. Kettel LM, Murphy AA, Morales AJ, Yen SS: Preliminary report on the treatment of endometriosis with low-dose mifepristone (RU 486). Am J Obstet Gynecol. 1998, 178 (6): 1151-1156.
3. Eisinger SH, Meldrum S, Fiscella K, le Roux HD, Guzick DS: Low-dose mifepristone for uterine leiomyomata. Obstet Gynecol. 2003, 101 (2): 243-250.
4. Murphy AA, Morales AJ, Kettel LM, Yen SS: Regression of uterine leiomyomata to the antiprogesterone RU486: dose–response effect. Fertil Steril. 1995, 64 (1): 187-190.
5. Steinauer J, Pritts EA, Jackson R, Jacoby AF: Systematic review of mifepristone for the treatment of uterine leiomyomata. Obstet Gynecol. 2004, 103 (6): 1331-1336.
Cited by
44 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献